Why is Kilitch Drugs falling/rising?

As of 18-Sep, Kilitch Drugs (India) Ltd is experiencing a decline in its stock price, currently at 363.35, which reflects a decrease of 0.5 or 0.14%. The stock has underperformed its sector by 1.19% today and has shown a trend reversal after two consecutive days of gains. Additionally, the stock's performance over the past month has been notably poor, with a decline of 14.22%, while it has seen a year-to-date increase of 12.49%. The company has a low Debt to Equity ratio, indicating a stable financial structure, but it also suffers from poor management efficiency, as evidenced by a low Return on Equity (ROE) of 7.27%. Recent financial results have shown a significant drop in profitability, with a 54% fall in profit after tax compared to previous quarters, contributing to negative sentiment around the stock.
Broader market context indicates that the stock's short-term performance has lagged behind the benchmark, with the Sensex rising by 1.80% over the past week while Kilitch Drugs only increased by 0.26%. This underperformance, coupled with a decrease in investor participation—evidenced by a 14.8% drop in delivery volume—suggests a lack of confidence among investors. The stock's valuation appears expensive relative to its peers, despite a significant increase in profits over the past year, which may deter potential buyers. The absence of domestic mutual fund investment further highlights a cautious outlook on the stock, as these funds typically conduct thorough research before committing capital.